Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acinetobacter Infections Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.

NCT03680898
View directory record Official record
Conditions
Carbapenem-Resistant Enterobacteriaceae
Interventions
Rectal swab collection
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Indianapolis, Indiana • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jun 26, 2026, 12:27 PM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol

NCT00524290
View directory record Official record
Conditions
Acinetobacter Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria

NCT01481935
View directory record Official record
Conditions
Infection Control
Interventions
Enhanced cleaning of surfaces in ICU rooms, Sham enhanced cleaning of surfaces in ICU rooms
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Not applicable Interventional

Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)

NCT01579370
View directory record Official record
Conditions
Multidrug Resistant Organisms, Healthcare Associated Infections
Interventions
Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light, Bleach and UV-C light
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria

NCT01041716
View directory record Official record
Conditions
Drug Resistance, Microbial
Interventions
None - Observational study
Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Clinical Outcomes and Global Epidemiology -Data Coordinating Center

NCT00524563
View directory record Official record
Conditions
Acinetobacter Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Risk Factors for Carbapenem-resistant Acinetobacter Baumannii

NCT00462579
View directory record Official record
Conditions
Acinetobacter Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions
Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

NCT04018950
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514, 14C-ETX2514
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jun 26, 2026, 12:27 PM EDT
Recruiting Not applicable Interventional

Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System

NCT04900298
View directory record Official record
Conditions
Surgical Wound Infection, Cross Infection
Interventions
SafeHaven Automated Hand Hygiene Device
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

NCT02060513
View directory record Official record
Conditions
Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions
Not listed
Lead sponsor
Connie Price
Other
Eligibility
18 Years and older
Enrollment
2,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 26, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)

NCT01919762
View directory record Official record
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Jun 26, 2026, 12:27 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

NCT06746883
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Non-interventional
Other
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

NCT03985410
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514, Placebo, moxifloxacin
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jun 26, 2026, 12:27 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06801223
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Drug
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
1 Day to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 26, 2026, 12:27 PM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism Network

NCT03646227
View directory record Official record
Conditions
Infections Resistant to Multiple Drugs, Bacterial Infections
Interventions
Standard of Care
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
6,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Jun 26, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Intraoperative Infection Transmission in the Pediatric Operating Room

NCT03992209
View directory record Official record
Conditions
Health Care Associated Infection, Hand Hygiene
Interventions
Standard care, Protocolized care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Jun 26, 2026, 12:27 PM EDT
Active, not recruiting No phase listed Observational

Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

NCT07226557
View directory record Official record
Conditions
Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 26, 2026, 12:27 PM EDT